BrainCool’s CEO on the listing announcement from Nasdaq
BrainCool has received conditional approval for admission to trading on the Nasdaq First North Growth Market. Talking to BioStock, CEO Martin Waleij says that...
PHI catches eye of major investor
The private Swiss Distributor and Investment Company Altium has acquired a corner of Swedish medtech company Phase Holographic Imaging, making them its largest owner....
Saniona sees potential for value-creating milestones
After a 2022 with both ups and downs, Saniona is fully focused on pipeline development and partnership discussions. BioStock contacted CEO Thomas Feldthus to...
AI opens up opportunities in healthcare
Artificial intelligence, AI, is a growing field that is expected to have great importance in healthcare and the life science sector. Already today, several...
Cereno Scientific’s CBO about his new role
Cereno Scientific’s clinical and preclinical programmes in cardiovascular disease are progressing strongly. In light of that, the company has been taking steps to ensure...
Stayble adds disc herniation to the pipeline – study approved
The pharmaceutical company Stayble Therapeutics has received approval to initiate a clinical phase Ib study with STA363 in patients suffering from chronic disc herniation....
Stem cell therapy for Parkinson’s disease reaches milestone
The first of a total of eight patients with Parkinson's disease has now received a stem cell transplant in the phase I/II STEM-PD clinical...
Saliva samples detects early signs of Alzheimer’s and Parkinson’s
Researchers at Luleå University of Technology suggest a new strategy to diagnose neurological diseases. By using molecules from the brain that can be measured...
Saniona´s obesity drug one step closer to approval
The Mexican regulatory authority technical committee on new molecules has provided a favourable opinion on Saniona´s drug candidate tesofensine for the treatment of obesity....
Chordate makes progress in Italy, China and Saudi Arabia
Chordate Medical's year-end report for 2022 does not show very large sales for either the full year nor the fourth quarter. However, the company's...
